|
Active substance |
Osimertinib |
|
Holder |
AstraZeneca SA/NV |
|
Status |
Closed |
|
Indication |
Tagrisso® is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). |
|
Public documents |
|
|
Last update |
01/12/2016 |
Tagrisso®
Last updated on 13/09/2024